Are obliterative pulmonary vascular lesions reversible?
Are obliterative pulmonary vascular lesions reversible?
复制标题
DOI：
10.1164/rccm.201106-1095ed
复制
发表时间：
2011-08
影响因子：
24.7
通讯作者：
J. West
中科院分区：
文献类型：
--
作者：
J. West
第纳尔功能趋势。[J]呼吸急救医学2003；168:531 - 537。2. Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK。临床和生理变量的变化预测特发性肺纤维化患者的生存。[J]中华呼吸与急救杂志2003；16(3):538 - 542。3. Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, Travis WD, Flint A, Toews GB， Lynch JP III等。特发性间质性肺炎的生理和影像学改变对预后的影响。[J]呼吸急救医学2003；168: 543 - 548。4. 马丁内斯FJ， Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr, Flaherty KR, Schwartz DA, Noble PW, Raghu G，等。特发性肺纤维化患者的临床病程。Ann Intern Med 2005; 142:693-697。5. Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, King TE Jr，特发性肺纤维化研究小组。干扰素γ -1b在特发性肺纤维化患者中的安慰剂对照试验中华医学杂志，2004;35(1):105 - 105。6. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F，等。高剂量乙酰半胱氨酸在特发性肺纤维化中的作用。中华医学杂志2005；353:2229 - 2242。7. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A，等。特发性肺纤维化患者个体死亡风险的确定。[J]中华呼吸与急救医学杂志，2011;19(4):459 - 466。8. King Te Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L，等。干扰素γ -1b对特发性肺纤维化（INSPIRE）患者生存率的影响：一项多中心随机安慰剂对照试验《柳叶刀》2009年;374:222 - 228。9. SelmanM, Carrillo G, Estrada A,Mejia M, Becerril C, Cisneros J, Gaxiola M, psamrez - padilla R, Navarro C, Richards T，等。特发性肺纤维化的加速变异：临床行为和基因表达模式。科学通报，2007;22(2):482。10. Boon K, Bailey NW, Yang J, Steel MP, Groshong S, Kervitsky D, Brown KK, Schwarz MI, Schwartz DA。分子表型区分相对稳定型和进行性特发性肺纤维化（IPF）患者。科学通报，2009;4:51 - 54。11. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Sahn SA, Szwarcberg J，等。六分钟步行试验在特发性肺纤维化：试验验证和最小的临床重要差异。[J] .中华呼吸与急救医学杂志，2011;33(3):1231 - 1237。12. Wells AU, King AD, Rubens MB, Cramer D, du Bois RM, Hansell DM, Lone CFA。基于薄层计算机断层扫描疾病程度的功能-形态学关联。[J]中华呼吸与急救医学杂志1997；15(5):397 - 397。13. Schmidt SL, Nambiar AM, Tayob N, Sundaram B, Han MK, Gross BH, Kazerooni EA, Chugtai AR, Lagstein A， Myers JL等。肺功能测量预测特发性肺纤维化与合并肺纤维化和肺气肿的死亡率不同。中国生物医学工程杂志，2011;38(4):391 - 391。14. Zappala CJ, Latsi PI, Nicholson AG, Colby TV, Cramer D, Renzoni EA, Hansell DM, du Bois RM, Wells AU。FVC的边际下降与特发性肺纤维化的不良预后相关。中国生物医学工程学报，2010;35(5):893 - 893。15. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA，等。ATS/ERS/ JRS/ALAT官方声明：特发性肺纤维化：诊断和管理的循证指南。[J]中华呼吸与急救医学杂志，2011;43(3):888 - 888。
dinal functional trends. Am J Respir Crit Care Med 2003;168:531– 537. 2. Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168:538–542. 3. Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, Travis WD, Flint A, Toews GB, Lynch JP III, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003;168: 543–548. 4. Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr, Flaherty KR, Schwartz DA, Noble PW, Raghu G, et al. The clinical course of subjects with idiopathic pulmonary fibrosis. Ann Intern Med 2005;142:693–697. 5. Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, King TE Jr, Idiopathic Pulmonary Fibrosis Study Group. A placebocontrolled trial of interferon gamma-1b in subjects with idiopathic pulmonary fibrosis. N Engl J Med 2004;350:125–133. 6. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353:2229–2242. 7. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;184:459–466. 8. King Te Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, et al. Effect of interferon gamma-1b om survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre randomised placebo-controlled trial. Lancet 2009;374:222–228. 9. SelmanM, Carrillo G, Estrada A,Mejia M, Becerril C, Cisneros J, Gaxiola M, Pérez-Padilla R, Navarro C, Richards T, et al. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS One 2007;2:e482. 10. Boon K, Bailey NW, Yang J, Steel MP, Groshong S, Kervitsky D, Brown KK, Schwarz MI, Schwartz DA. Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis (IPF). PLoS One 2009;4:e5134. 11. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, et al. Six-minute-walk test in diopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 2011;183:1231–1237. 12. Wells AU, King AD, Rubens MB, Cramer D, du Bois RM, Hansell DM, Lone CFA. a functional-morphological correlation based on extent of disease on thin-section computed tomography. Am J Respir Crit Care Med 1997;155:1367–1375. 13. Schmidt SL, Nambiar AM, Tayob N, Sundaram B, Han MK, Gross BH, Kazerooni EA, Chugtai AR, Lagstein A, Myers JL, et al. Pulmonary function measures predict mortality differently in idiopathic pulmonary fibrosis versus combined pulmonary fibrosis and emphysema. Eur Respir J 2011;38:176–183. 14. Zappala CJ, Latsi PI, Nicholson AG, Colby TV, Cramer D, Renzoni EA, Hansell DM, du Bois RM, Wells AU. Marginal decline in FVC is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2010;35:830–836. 15. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et al. An official ATS/ERS/ JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;83:788–824.